The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer

Trastuzumab, an anti-ErbB2 humanized antibody, brings benefit to patients with ErbB2-amplified metastatic breast cancers. However, the resistance to trastuzumab is common. Our previously reported H2-18, an anti-ErbB2 antibody, potently induced programmed cell death in trastuzumab-resistant breast ca...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Wang, Lingfei, Yu, Xiaojie, Wang, Chao, Pan, Shujun, Liang, Beibei, Zhang, Yajun, Chong, Xiaodan, Meng, Yanchun, Dong, Jian, Zhao, Yirong, Yang, Yang, Wang, Huajing, Gao, Jie, Wei, Huafeng, Zhao, Jian, Wang, Hao, Hu, Chaohua, Xiao, Wenze, Li, Bohua
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2017
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5581078/
https://ncbi.nlm.nih.gov/pubmed/28881779
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17907
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items